Thursday, June 1, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

FDA Puts Anthrax Vaccine on Clinical Hold Again

by Global Biodefense Staff
December 17, 2013

PharmAthene, Inc. announced this week it has received notification from the U.S. Food and Drug Administration (FDA) that its SparVax anthrax vaccine program has again been placed on clinical hold.

SparVax is a next-generation recombinant protective anthrax vaccine being developed for pre- and postexposure protection against anthrax infection. The vaccine has previously been evaluated in three separate Phase 1 and Phase 2 clinical trials involving 770 healthy human subjects.

An earlier clinical hold was enacted in August 2012, prior to the commencement of a proposed Phase II clinical trial of SparVax, requiring PharmAthene provide additional stability data for both its engineering and GMP lots of U.S. manufactured Final Drug Product of SparVax. The hold was lifted by the FDA in May 2013.

Announcement of the clinical hold comes just weeks after PharmAthene announced it had called off a planned merger with Theraclone Sciences, maker of therapeutic antibodies for applications including pandemic or resistant influenza.

The FDA indicated that PharmAthene will receive a letter providing details of the basis for the clinical hold within thirty days. The Phase II clinical study, which was expected to begin by the end of this year, has not enrolled any subjects to date and accordingly, there have been no adverse events reported.

Tags: AnthraxBioterrorismVaccines

Related Posts

Vials of finished vaccines
Funding News

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics
Industry News

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023
Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC